Literature DB >> 33269021

MR-proADM and MR-proANP levels in patients with acute pulmonary embolism.

Önsel Öner1, Figen Deveci1, Selda Telo2, Mutlu Kuluöztürk1, Mehmet Balin3.   

Abstract

BACKGROUND: The aim of this study was to determine levels of Mid-regional Pro-adrenomedullin (MR-proADM) and Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) in patients with acute pulmonary embolism (PE), the relationship between these parameters and the risk classification in addition to determining the relationship between 1and 3month mortality.
METHODS: 82 PE patients and 50 healthy control subjects were included in the study. Blood samples for Mr-proANP and Mr-proADM were obtained from the subjects prior to the treatment. Risk stratification was determined according to sPESI (Simplified Pulmonary Embolism Severity Index). Following these initial measurements, cases with PE were assessed in terms of all causative and PE related mortalities.
RESULTS: The mean serum Mr-proANP and Mr-proADM levels in acute PE patients were found to be statistically higher compared to the control group (p < 0.001, p < 0.01; respectively) and statistically significantly higher in high-risk patients than low-risk patients (p < 0.01, p < 0.05; respectively). No statistical difference was determined in high-risk patients in case of sPESI compared to low-risk patients while hospital mortality rates were higher. It was determined that the hospital mortality rate in cases with Mr-proANP ≥ 123.30 pmol/L and the total 3-month mortality rate in cases with Mr-proADM ≥ 152.2 pg/mL showed a statistically significant increase.
CONCLUSIONS: This study showed that Mr-proANP and MRproADM may be an important biochemical marker for determining high-risk cases and predicting the mortality in PE patients and we believe that these results should be supported by further and extensive studies. 2020 Önsel Öner, Figen Deveci, Selda Telo, Mutlu Kuluöztürk, Mehmet Balin, published by CEON/CEES.

Entities:  

Keywords:  MRproANP; Mr-proADM; mortality; pulmonary embolism

Year:  2020        PMID: 33269021      PMCID: PMC7682857          DOI: 10.2478/jomb-2019-0049

Source DB:  PubMed          Journal:  J Med Biochem        ISSN: 1452-8266            Impact factor:   3.402


  29 in total

1.  Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.

Authors:  Justyna Pedowska-Włoszek; Maciej Kostrubiec; Katarzyna Kurnicka; Michal Ciurzynski; Piotr Palczewski; Piotr Pruszczyk
Journal:  Thromb Res       Date:  2013-08-19       Impact factor: 3.944

2.  Distribution and correlates of midregional proadrenomedullin in the general population.

Authors:  J Gustav Smith; Christopher Newton-Cheh; Bo Hedblad; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Thomas J Wang; Olle Melander
Journal:  Clin Chem       Date:  2009-06-18       Impact factor: 8.327

3.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

Authors:  Alan Maisel; Christian Mueller; Richard Nowak; W Frank Peacock; Judd W Landsberg; Piotr Ponikowski; Martin Mockel; Christopher Hogan; Alan H B Wu; Mark Richards; Paul Clopton; Gerasimos S Filippatos; Salvatore Di Somma; Inder Anand; Leong Ng; Lori B Daniels; Sean-Xavier Neath; Robert Christenson; Mihael Potocki; James McCord; Garret Terracciano; Dimitrios Kremastinos; Oliver Hartmann; Stephan von Haehling; Andreas Bergmann; Nils G Morgenthaler; Stefan D Anker
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

4.  Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

Authors:  Alan Maisel; Christian Mueller; Richard M Nowak; W Frank Peacock; Piotr Ponikowski; Martin Mockel; Christopher Hogan; Alan H B Wu; Mark Richards; Paul Clopton; Gerasimos S Filippatos; Salvatore Di Somma; Inder Anand; Leong L Ng; Lori B Daniels; Sean-Xavier Neath; Robert Christenson; Mihael Potocki; James McCord; Oliver Hartmann; Nils G Morgenthaler; Stefan D Anker
Journal:  J Am Coll Cardiol       Date:  2011-08-30       Impact factor: 24.094

5.  Long-term Prognosis in COPD Exacerbation: Role of Biomarkers, Clinical Variables and Exacerbation Type.

Authors:  Eva Grolimund; Alexander Kutz; Robert J Marlowe; Alaadin Vögeli; Murat Alan; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Claus Hoess; Christoph Henzen; Werner Zimmerli; Beat Mueller; Philipp Schuetz
Journal:  COPD       Date:  2014-09-17       Impact factor: 2.409

6.  Right ventricle dysfunction and pulmonary hypertension in hemodynamically stable pulmonary embolism.

Authors:  Rafael Golpe; Luis A Pérez-de-Llano; Olalla Castro-Añón; Manuel Vázquez-Caruncho; Carlos González-Juanatey; Alejandro Veres-Racamonde; Concepción Iglesias-Moreira; María Carmen Fariñas
Journal:  Respir Med       Date:  2010-04-24       Impact factor: 3.415

Review 7.  Pulmonary embolism: risk assessment and management.

Authors:  Stavros Konstantinides; Samuel Z Goldhaber
Journal:  Eur Heart J       Date:  2012-09-07       Impact factor: 29.983

8.  Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.

Authors:  Daiana Stolz; Mirjam Christ-Crain; Nils G Morgenthaler; David Miedinger; Jörg Leuppi; Christian Müller; Roland Bingisser; Joachim Struck; Beat Müller; Michael Tamm
Journal:  Chest       Date:  2008-05-19       Impact factor: 9.410

9.  Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease.

Authors:  C D Vizza; C Letizia; S Sciomer; R Naeije; G Della Rocca; A Di Roma; S Musarò; S Quattrucci; C Gaudio; A Battagliese; R Badagliacca; E D'Erasmo; F Fedele
Journal:  Regul Pept       Date:  2005-01-15

10.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).

Authors:  Stavros V Konstantinides; Guy Meyer; Cecilia Becattini; Héctor Bueno; Geert-Jan Geersing; Veli-Pekka Harjola; Menno V Huisman; Marc Humbert; Catriona Sian Jennings; David Jiménez; Nils Kucher; Irene Marthe Lang; Mareike Lankeit; Roberto Lorusso; Lucia Mazzolai; Nicolas Meneveau; Fionnuala Ní Áinle; Paolo Prandoni; Piotr Pruszczyk; Marc Righini; Adam Torbicki; Eric Van Belle; José Luis Zamorano
Journal:  Eur Heart J       Date:  2020-01-21       Impact factor: 35.855

View more
  1 in total

1.  Genetic polymorphism of matrix metalloproteinase 9 and susceptibility to chronic obstructive pulmonary disease: A meta-analysis.

Authors:  Xiaoping Yang; Yuanyuan Yu; Yong Wang; Wen Jiang; Wenqing Jiang; Bin Yin
Journal:  J Med Biochem       Date:  2022-07-29       Impact factor: 2.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.